Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACK study of Trelegy Ellipta versus umeclidinium + vilanterol in mild to moderate COPD
jRCTs071210124Completed
- Sponsor
- GSK
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Trial of fluticasone, umeclidinium and vilanterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Average change in trough FEV1 from baseline after 12 weeks. Started Feb 2022; status: completed.
02
Drugs
fluticasoneumeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCTs071210124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071210124.